-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on CalciMedica, Lowers Price Target to $10

Benzinga·03/05/2026 17:55:04
Listen to the news
Oppenheimer analyst Leland Gershell maintains CalciMedica (NASDAQ:CALC) with a Outperform and lowers the price target from $20 to $10.